This early-stage study tests a single dose of a new long-acting antibody in 20 people with HIV who are not on treatment. The goal is to check safety and see if the antibody can lower the amount of virus in the blood. Results will help design future studies for both HIV prevention…
Phase: PHASE1 • Sponsor: David Ho • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC